In this episode of Believe in Progress, Trevor Maxwell talks with Mitch about his cancer journey. Trevor, 45, has been living with stage IV colon cancer since March 2018. He has undergone five major surgeries, chemotherapy, immunotherapy, and participated in a clinical trial. In January 2020, Trevor founded Man Up to Cancer, a purpose-driven company and support community that inspires men to connect and avoid isolation during their cancer journeys. Trevor has a background in newspaper journalism and is writing a book: “Open Heart, Warrior Spirit: A Man’s Guide to Living With Cancer.”
A new study suggests steroids could blunt the effects of some immunotherapies, but researchers say they remain necessary for some patients.
by Kyle Bagenstose
Treatment Combination Improves Survival in Platinum-resistant Ovarian CancerPreliminary results found that combining relacorilant with nab-paclitaxel improved outcomes for women with advanced ovarian cancer.
by Sandra Gordon
CAR T-cell Therapy Shows Response in Rare Brain CancerPotential new approach to treating diffuse intrinsic pontine glioma uses engineered immune cells infused directly to the brain.
by Taneia Surles
Technology’s Changing Role in Cancer CareExperts explain how artificial intelligence, nanotechnology and decentralized care are poised to improve research, detection and treatment.
by Thomas Celona
Support for Cancer Today has been provided in part by an independent educational grant from Merck & Co., Inc.
All editorial content is produced independently by the Cancer Today editorial team.
-
Ultraproccessed Foods and Cancer RiskThe idea that ultraprocessed foods are associated with increased risk of metabolic and cardiovascular diseases is well supported, but what does the evidence reveal about these foods and cancer?
-
What Are the Benefits of Exercise for Cancer Patients?Several recent studies have explored how exercise can impact a cancer patient’s survival, risk of recurrence, and overall quality of life.
Cancer Research at a Crossroads
Support for Cancer Today has been provided in part by an independent educational grant from Merck & Co., Inc.
All editorial content is produced independently by the Cancer Today editorial team.
